{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:41:17Z","timestamp":1792503677006,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s10875-010-9407-4","type":"journal-article","created":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T02:27:53Z","timestamp":1271298473000},"page":"74-78","source":"Crossref","is-referenced-by-count":93,"title":["IVIG Treatment and Prognosis in Guillain\u2013Barr\u00e9 Syndrome"],"prefix":"10.1007","volume":"30","author":[{"given":"Pieter A.","family":"van Doorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Kuitwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Walgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinske","family":"van Koningsveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte","family":"Ruts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,16]]},"reference":[{"key":"9407_CR1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","volume":"366","author":"RA Hughes","year":"2005","unstructured":"Hughes RA, Cornblath DR. Guillain\u2013Barr\u00e9 syndrome. Lancet. 2005;366:1653\u201366.","journal-title":"Lancet"},{"key":"9407_CR2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA Doorn van","year":"2008","unstructured":"van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain\u2013Barr\u00e9 syndrome. Lancet Neurol. 2008;7:939\u201350.","journal-title":"Lancet Neurol"},{"key":"9407_CR3","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","volume":"51","author":"BC Jacobs","year":"1998","unstructured":"Jacobs BC, Rothbarth PH, van der Mech\u00e9 FG, Herbrink P, Schmitz PI, de Klerk MA, et al. The spectrum of antecedent infections in Guillain\u2013Barr\u00e9 syndrome: a case-control study. Neurology. 1998;51:1110\u20135.","journal-title":"Neurology"},{"key":"9407_CR4","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain\u2013Barr\u00e9 syndrome. Ann Neurol. 1990;27:S21\u20134.","journal-title":"Ann Neurol"},{"key":"9407_CR5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","volume":"10","author":"HJ Willison","year":"2005","unstructured":"Willison HJ. The immunobiology of Guillain\u2013Barr\u00e9 syndromes. J Peripher Nerv Syst. 2005;10:94\u2013112.","journal-title":"J Peripher Nerv Syst"},{"key":"9407_CR6","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/brain\/awh231","volume":"127","author":"SK Halstead","year":"2004","unstructured":"Halstead SK, O'Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, Todd AJ, et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain. 2004;127:2109\u201323.","journal-title":"Brain"},{"key":"9407_CR7","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","volume":"27","author":"K Susuki","year":"2007","unstructured":"Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 2007;27:3956\u201367.","journal-title":"J Neurosci"},{"key":"9407_CR8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","volume":"131","author":"SK Halstead","year":"2008","unstructured":"Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131:1197\u2013208.","journal-title":"Brain"},{"key":"9407_CR9","doi-asserted-by":"crossref","unstructured":"Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev. CD002063, 2006.","DOI":"10.1002\/14651858.CD002063.pub3"},{"key":"9407_CR10","doi-asserted-by":"crossref","unstructured":"Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev. CD001798, 2002.","DOI":"10.1002\/14651858.CD001798"},{"key":"9407_CR11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG Mech\u00e9 van der","year":"1992","unstructured":"van der Mech\u00e9 FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome. Dutch Guillain\u2013Barr\u00e9 Study Group. N Engl J Med. 1992;326:1123\u20139.","journal-title":"N Engl J Med"},{"key":"9407_CR12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group","year":"1997","unstructured":"Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barr\u00e9 syndrome. Lancet. 1997;349:225\u201330.","journal-title":"Lancet"},{"key":"9407_CR13","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"RA Hughes","year":"2007","unstructured":"Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain\u2013Barr\u00e9 syndrome: a systematic review. Brain. 2007;130:2245\u201357.","journal-title":"Brain"},{"key":"9407_CR14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R Koningsveld van","year":"2004","unstructured":"van Koningsveld R, Schmitz PI, Mech\u00e9 FG, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome: randomised trial. Lancet. 2004;363:192\u20136.","journal-title":"Lancet"},{"key":"9407_CR15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1212\/WNL.58.4.610","volume":"58","author":"R Koningsveld van","year":"2002","unstructured":"van Koningsveld R, Schmitz PI, Ang CW, Groen J, Osterhaus AD, van der Mech\u00e9 FG, et al. Infections and course of disease in mild forms of Guillain\u2013Barr\u00e9 syndrome. Neurology. 2002;58:610\u20134.","journal-title":"Neurology"},{"key":"9407_CR16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(06)70603-2","volume":"5","author":"MC Durand","year":"2006","unstructured":"Durand MC, Porcher R, Orlikowski D, Aboab J, Devaux C, Clair B, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain\u2013Barr\u00e9 syndrome: a prospective study. Lancet Neurol. 2006;5:1021\u20138.","journal-title":"Lancet Neurol"},{"key":"9407_CR17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R Koningsveld van","year":"2007","unstructured":"van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain\u2013Barr\u00e9 syndrome. Lancet Neurol. 2007;6:589\u201394.","journal-title":"Lancet Neurol"},{"key":"9407_CR18","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(97)24050-X","volume":"350","author":"P Farcas","year":"1997","unstructured":"Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain\u2013Barr\u00e9 syndrome. Lancet. 1997;350:1747.","journal-title":"Lancet"},{"key":"9407_CR19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain\u2013Barr\u00e9 syndrome. Ann Neurol. 2009;66:597\u2013603.","journal-title":"Ann Neurol"},{"key":"9407_CR20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.21816","volume":"66","author":"DR Cornblath","year":"2009","unstructured":"Cornblath DR, Hughes RA. Treatment for Guillain\u2013Barr\u00e9 syndrome. Ann Neurol. 2009;66:569\u201370.","journal-title":"Ann Neurol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-010-9407-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:17:55Z","timestamp":1559027875000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-010-9407-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,16]]},"references-count":20,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["9407"],"URL":"https:\/\/doi.org\/10.1007\/s10875-010-9407-4","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,16]]}}}